NetScientific PLC Result of Placing (8066H)
June 12 2017 - 5:10AM
UK Regulatory
TIDMNSCI
RNS Number : 8066H
NetScientific PLC
12 June 2017
12 June 2017
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION,
DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED
STATES OF AMERICA, THE REPUBLIC OF Ireland, AUSTRALIA, CANADA,
JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN
WHICH IT WOULD BE UNLAWFUL TO DO SO.
THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR THE SOLICITATION OF
AN OFFER TO BUY ANY ORDINARY SHARES OR OTHER SECURITIES OF THE
COMPANY AND NEITHER THIS ANNOUNCEMENT NOR ANYTHING HEREIN FORMS THE
BASIS FOR ANY CONTRACT OR COMMITMENT WHATSOEVER. ORDINARY SHARES OR
OTHER SECURITIES OF THE COMPANY MAY NOT BE OFFERED OR SOLD IN THE
UNITED STATES OF AMERICA ABSENT REGISTRATION OR AN EXEMPTION FROM
REGISTRATION AND THE ORDINARY SHARES DESCRIBED HEREIN WILL BE SOLD
IN ACCORDANCE WITH ALL APPLICABLE LAWS AND REGULATIONS.
NetScientific plc
("NetScientific" or the "Company")
Result of Placing, Subscription and Additional Fundraising
London, UK - 12 June 2017: On 25 May 2017, NetScientific, the
transatlantic healthcare IP commercialisation Group, announced a
conditional Placing and Subscription to raise approximately
GBP8.1m, (the "Initial Offer"), and an Additional Fundraising (the
"Additional Fundraising") both before expenses.
The Additional Fundraising closed for acceptances at 11.00 a.m.
on 9 June 2017. The Company is pleased to announce that it has
received valid requests for subscriptions in respect of 45,700
Additional Fundraising Shares. This represents 0.1 per cent. of the
Company's share capital as enlarged by the Initial Offer and the
Additional Fundraising. The Company has therefore raised a total of
GBP8.1 million, before expenses, from Initial Offer and Additional
Fundraising.
The New Ordinary Shares to be issued pursuant to the Initial
Offer and Additional Fundraising remain subject to the passing of
the Resolutions at the General Meeting to be held at the offices of
DLA Piper UK LLP, 3 Noble St, London EC2V 7EE at 11.00 a.m. today
and Admission (as defined below).
Capitalised terms in this announcement have the meanings given
to them in the Circular dated 26 May 2017.
Applications have been made to the London Stock Exchange for
17,962,362 New Ordinary Shares to be admitted to trading on AIM
("Admission"). Admission, subject to the passing of the
Resolutions, is expected to commence at 8.00 am on 13 June 2017.
Following Admission, the New Ordinary Shares will rank pari passu
with the existing Ordinary Shares.
On Admission, the Company's issued share capital will comprise
69,038,057 Ordinary Shares, none of which will be held in treasury.
Each Ordinary Share carries the right to one vote and therefore the
total number of voting rights in the Company on admission will be
69,038,057. This figure may be used by shareholders and other
investors as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
change to their interest in, the Company under the FCA's Disclosure
and Transparency Rules.
Inside Information
This announcement contains inside information. The person
responsible for arranging for the release of this announcement on
behalf of the Company is Ian Postlethwaite, the Company's Chief
Financial Officer.
A copy of this announcement has been posted on the Company's
website at http://www.netscientific.net/
For more information, please contact:
NetScientific plc
François R. Martelet, M.D., Tel: +44 (0)20
CEO 3514 1800
Ian Postlethwaite, CFO
Stifel Nicolaus Europe Limited Tel: +44 (0)20
(NOMAD, broker and bookrunner) 7710 7600
Jonathan Senior / David Arch /
Ben Maddison
Liberum Capital Limited (placing Tel: +44 (0)20
agent) 3100 2000
David Parsons / Christopher Britton
Consilium Strategic Tel: +44 (0)20 3709 5700
Communications
Mary-Jane Elliott /
Jessica Hodgson / Chris
Welsh / Laura Thornton
netscientific@consilium-comms.com
About NetScientific
NetScientific is an IP commercialisation group focused on
healthcare with an investment strategy focused on sourcing, funding
and commercialising technologies that significantly improve the
health and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
Stifel Nicolaus Europe Limited ("Stifel") is authorised and
regulated by the FCA in the United Kingdom and is acting
exclusively as nominated adviser and bookrunner to the Company (for
the purposes of the AIM Rules for Companies) and no one else in
connection with Admission, the Placing and the matters set out in
this announcement. Stifel will not regard any other person as its
customer or be responsible to any other person for providing the
protections afforded to customers of Stifel nor for providing
advice in relation to the transactions and arrangements detailed in
this announcement for which the Company and the Directors are
solely responsible and, without limiting the statutory rights of
any recipient of this announcement, no liability is accepted by
Stifel for the accuracy of any information or opinions contained in
this announcement or for omissions of any material information for
which it is not responsible. Stifel is not making any
representation or warranty, express or implied, as to the contents
of this announcement. The responsibilities of Stifel as the
Company's nominated adviser and bookrunner solely for the purposes
of the AIM Rules for Nominated Advisers are owed solely to the
London Stock Exchange and are not owed to the Company or any
Director or to any other person in respect of his decision to
invest in the Company in reliance on any parts of this
announcement.
Liberum Capital Limited ("Liberum"), which is authorised and
regulated in the United Kingdom by the FCA, is acting exclusively
for the Company and no other person in connection with the Placing.
Liberum will not regard any other person as its customer or be
responsible to any other person for providing the protections
afforded to customers of Liberum nor for providing advice in
relation to the transactions and arrangements detailed in this
announcement for which the Company and the Directors are solely
responsible and, without limiting the statutory rights of any
person to whom this announcement is issued, no liability is
accepted by Liberum for the accuracy of any information or opinions
contained in this announcement or for the omission of any material
information for which it is not responsible. Liberum is not making
any representation or warranty, express or implied, as to the
contents of this announcement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOELLFIIRDIFLID
(END) Dow Jones Newswires
June 12, 2017 06:10 ET (10:10 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024